Cargando…

P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY

Detalles Bibliográficos
Autores principales:	Kuruvilla, J., Armand, P., Herrera, A. F., Ribrag, V., Brice, P., Thieblemont, C., Von Tresckow, B., Kim, E., Marinello, P., Chakraborty, S., Orlowski, R., Zinzani, P. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431124/ http://dx.doi.org/10.1097/01.HS9.0000848268.24972.7c

Ejemplares similares

An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013
por: Ribrag, Vincent, et al.
Publicado: (2015)

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
por: Armand, Philippe, et al.
Publicado: (2023)

Pembrolizumab in relapsed or refractory Richter syndrome
por: Armand, Philippe, et al.
Publicado: (2020)

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170
por: Zinzani, Pier Luigi, et al.
Publicado: (2023)

Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study
por: Gregory, Gareth P., et al.
Publicado: (2022)

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
por: Armand, Philippe, et al.
Publicado: (2019)

Allogeneic hematopoietic stem cell transplantation for non-malignant hematological disorders
por: Mahmoud, Hossam K., et al.
Publicado: (2015)

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies
por: Zahid, Mohammad Faizan, et al.
Publicado: (2014)

Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies
por: Pavletic, ZS, et al.
Publicado: (1998)

Rapid cardiovascular aging following allogeneic hematopoietic cell transplantation for hematological malignancy
por: Dillon, Hayley T., et al.
Publicado: (2022)

Primary Graft Failure after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
por: Olsson, Richard F., et al.
Publicado: (2015)

P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY
por: Gregory, G., et al.
Publicado: (2022)

Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087
por: Chen, Robert, et al.
Publicado: (2015)

Outcomes of two-step haploidentical allogeneic stem cell transplantation in elderly patients with hematologic malignancies
por: Bi, Xia, et al.
Publicado: (2022)

Infectious complications after second allogeneic hematopoietic cell transplant in adult patients with hematological malignancies
por: Maurer, Stephen M., et al.
Publicado: (2022)

Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation
por: Godfrey, James, et al.
Publicado: (2022)

Clinicopathologic characteristics of secondary squamous cell carcinoma of head and neck in survivors of allogeneic hematopoietic stem cell transplantation for hematologic malignancies
por: Chaulagain, Chakra P., et al.
Publicado: (2018)

Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria
por: Battipaglia, Giorgia, et al.
Publicado: (2019)

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades
por: Cooper, Jason P., et al.
Publicado: (2020)

Estimating the treatment effect from non-randomized studies: The example of reduced intensity conditioning allogeneic stem cell transplantation in hematological diseases
por: Resche-Rigon, Matthieu, et al.
Publicado: (2012)

P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY
por: Herrera, A. F., et al.
Publicado: (2022)

Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies
por: Xuan, Li, et al.
Publicado: (2012)

Very Long Term Stability of Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematologic Malignancies
por: Levrat, Emmanuel, et al.
Publicado: (2015)

1077. Infectious complications after second allogeneic hematopoietic cell transplant (allo-HCT) in adult patients with hematological malignancies
por: Maurer, Stephen, et al.
Publicado: (2020)

P1067: ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB WHEN USED IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA
por: Armand, Philippe, et al.
Publicado: (2023)

Treosulfan–fludarabine–thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies
por: Kalwak, Krzysztof, et al.
Publicado: (2020)

Anti-Thymocyte Globulin Prophylaxis in Patients With Hematological Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: An Updated Meta-Analysis
por: Yang, Xue, et al.
Publicado: (2021)

Interleukin-10-592 polymorphism: impact on relapse and survival after allogeneic hematopoietic stem cell transplantation in children with hematological malignancies
por: Schwenk, Laura, et al.
Publicado: (2021)

P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA
por: Johnson, Nathalie, et al.
Publicado: (2023)

Early report on the severity of COVID‐19 in hematologic patients infected with the SARS‐CoV2 omicron variant
por: Ullrich, Fabian, et al.
Publicado: (2022)

Pembrolizumab (MK-3475) in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-023
por: Mateos, Maria-Victoria, et al.
Publicado: (2015)

Pembrolizumab for treatment of progressive multifocal leukoencephalopathy in primary immunodeficiency and/or hematologic malignancy: a case series of five patients
por: Volk, Timo, et al.
Publicado: (2021)

Single center experience with total body irradiation and melphalan (TBI-MEL) myeloablative conditioning regimen for allogeneic stem cell transplantation (SCT) in patients with refractory hematologic malignancies
por: Bhatnagar, Bhavana, et al.
Publicado: (2013)

Allogeneic Stem Cell Transplantation for Patients with Advanced Hematological Malignancies: Comparison of Fludarabine-based Reduced Intensity Conditioning versus Myeloablative Conditioning
por: Kim, Inho, et al.
Publicado: (2007)

Late Toxicity of a Novel Allogeneic Stem Cell Transplant Using Single Fraction Total Body Irradiation for Hematologic Malignancies in Children
por: Madden, Lisa M., et al.
Publicado: (2015)

Results of an Innovative Program for Surveillance, Prophylaxis, and Treatment of Infectious Complications Following Allogeneic Stem Cell Transplantation in Hematological Malignancies (BATMO Protocol)
por: Malagola, Michele, et al.
Publicado: (2022)

Abstract 2 Results of an Open Label Expanded Access Study of Omidubicel-onlv for Allogeneic Transplantation (allo-HCT) in Patients with Hematologic Malignancies
por: Horwitz, Mitchell, et al.
Publicado: (2023)

Outcomes of allogeneic stem cell transplantation for patients with hematologic diseases ≥60 years old
por: Shima, Takahiro, et al.
Publicado: (2023)

Hematological malignancies presenting as spontaneous tumor lysis syndrome: A case series
por: Kollathodi, Shehla Basheer, et al.
Publicado: (2018)

The Confirmation of Safety for the Intensified Conditioning Regimens: A Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation for Non-Remission Hematological Malignant Diseases
por: Yoshida, Shuro, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5se047np9nr783n6errcu9olsj